Methods for Diagnosis and Treatment of Concussion or Brain Injury
AssigneeRhode Island Hospital
InventorsAdam Chodobski, Joanna Szmydynger-Chodobska
Life of this patent
Estimating the term…
Abstract
This invention relates to compositions and methods for diagnosing and treating concussion/mTBI.
Claims20
A method for identifying concussion or traumatic brain injury in a subject, comprising
- (1) providing a test sample from said subject, wherein said test sample comprises a bodily fluid;
- (2) performing a reaction in vitro by contacting said test sample with a binding agent to yield a complex comprising said binding agent and a protein selected from the group consisting of copeptin, MMP9, LGALS3, and OCLN, wherein said binding agent comprises a plurality of binding agents comprising a first binding agent that binds to copeptin, a second binding agent that binds to MMP9, a third binding agent that binds to LGALS3, and a fourth binding agent that binds to OCLN;
- (3) detecting said complex,
- wherein a decrease in the level of said complex comprising copeptin compared to a normal control and an increase in the level of said complex comprising MMP9, LGALS3, or OCLN compared to a normal control indicates concussion or traumatic brain injury in said subject.
A method for identifying concussion or traumatic brain injury in a subject, comprising
- (1) providing a test sample from said subject, wherein said test sample comprises a bodily fluid;
- (2) performing a reaction in vitro by contacting said test sample with a binding agent to yield a complex comprising said binding agent and a protein selected from the group consisting of copeptin, MMP9, LGALS3, and OCLN, wherein said binding agent comprises a plurality of binding agents comprising binding agents for at least two of said proteins;
- and
- (3) detecting said complex,
- wherein a decrease in the level of said complex comprising copeptin compared to a normal control or an increase in the level of said complex comprising MMP9, LGALS3, or OCLN compared to a normal control indicates concussion or traumatic brain injury in said subject.
A method for identifying concussion or traumatic brain injury in a subject, comprising
- (1) providing a test sample from said subject, wherein said test sample comprises a bodily fluid;
- (2) performing a reaction in vitro by contacting said test sample with a binding agent to yield a complex comprising said binding agent and a protein selected from the group consisting of copeptin, MMP9, LGALS3, and OCLN, wherein said binding agent comprises a plurality of binding agents comprising binding agents for at least three of said proteins;
- and
- (3) detecting said complex,
- wherein a decrease in the level of said complex comprising copeptin compared to a normal control or an increase in the level of said complex comprising MMP9, LGALS3, or OCLN compared to a normal control indicates concussion or traumatic brain injury in said subject.
A method of treating concussion or mTBI, comprising:
- (1) providing a test sample from a subject, wherein said test sample comprises a bodily fluid;
- (2) performing a reaction in vitro by contacting said test sample with a binding agent to yield a complex comprising said binding agent and a protein selected from the group consisting of copeptin, MMP9, LGALS3, and OCLN;
- (3) detecting said complex;
- wherein a decrease in the level of said complex comprising copeptin compared to a normal control and an increase in the level of said complex comprising MMP9, LGALS3, or OCLN compared to a normal control indicates concussion or traumatic brain injury in said subject;
- (4) administering to said subject a therapeutically effective amount of a compound that modulates the activity or level of said complex, thereby treating said subject.
A method of treating concussion or traumatic brain injury in a subject, comprising administrating to said subject a therapeutically effective amount of an MMP9 selective inhibitor or an LGALS3 selective inhibitor.
A diagnostic device comprising a solid support and a binding agent immobilized on said support, wherein said binding agent binds to a protein selected from the group consisting of copeptin, MMP9, LGALS3, and OCLN.
A diagnostic device comprising a solid support and a plurality of immobilized binding agents, wherein a first binding agent binds to copeptin, a second binding agent binds to MMP9, a third binding agent binds to LGALS3, or a fourth binding agent binds to OCLN.
Dependencies are inferred from the claim text.